↓ Skip to main content

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Readers on

mendeley
739 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Published in
Lancet Oncology, June 2018
DOI 10.1016/s1470-2045(18)30351-6
Pubmed ID
Authors

Andrew X Zhu, Richard S Finn, Julien Edeline, Stephane Cattan, Sadahisa Ogasawara, Daniel Palmer, Chris Verslype, Vittorina Zagonel, Laetitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L Chan, Jennifer Knox, Bruno Daniele, Andrea L Webber, Scot W Ebbinghaus, Junshui Ma, Abby B Siegel, Ann-Lii Cheng, Masatoshi Kudo, KEYNOTE-224 investigators, Angela Alistar, Jamil Asselah, Jean-Frederic Blanc, Ivan Borbath, Timothy Cannon, Ki Chung, Allen Cohn, David P Cosgrove, Nevena Damjanov, Mukul Gupta, Yoshivasu Karino, Mark Karwal, Andreas Kaubisch, Robin Kelley, Jena-Luc Van Laethem, Timothy Larson, James Lee, Daneng Li, Atisha Manhas, Gulam Abbas Manji, Kazushi Numata, Benjamin Parsons, Andrew S. Paulson, Carmine Pinto, Robert Ramirez, Suresh Ratnam, Magnus Rizell, Olivier Rosmorduc, Yvonne Sada, Yutaka Sasaki, Per I Stal, Simone Strasser, Joerg Trojan, Gina Vaccaro, Hans Van Vlierberghe, Alan Weiss, Karl-Heinz Weiss, Tatsuya Yamashita

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 77 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 739 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 739 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 109 15%
Student > Ph. D. Student 65 9%
Other 63 9%
Student > Master 57 8%
Student > Bachelor 54 7%
Other 117 16%
Unknown 274 37%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 245 33%
Biochemistry, Genetics and Molecular Biology 72 10%
Agricultural and Biological Sciences 29 4%
Immunology and Microbiology 19 3%
Pharmacology, Toxicology and Pharmaceutical Science 18 2%
Other 50 7%
Unknown 306 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 230. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 July 2026.
All research outputs
#210,866
of 34,779,718 outputs
Outputs from Lancet Oncology
#237
of 8,039 outputs
Outputs of similar age
#3,672
of 375,120 outputs
Outputs of similar age from Lancet Oncology
#4
of 115 outputs
Altmetric has tracked 34,779,718 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,039 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 39.5. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 375,120 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 115 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.